Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Reader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Avasarala J.

Neurology. 2018 Sep 18;91(12):580. doi: 10.1212/01.wnl.0000544324.09014.0e. No abstract available.

PMID:
30224507
2.

Reader Response: Practice Current: How do you treat neuromyelitis optica?

Avasarala J.

Neurol Clin Pract. 2018 Aug;8(4):276. doi: 10.1212/CPJ.0000000000000497. No abstract available.

PMID:
30140571
3.

Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?

Avasarala J, Parti N.

Front Neurol. 2018 Aug 8;9:613. doi: 10.3389/fneur.2018.00613. eCollection 2018.

4.

DRESS Syndrome and Daclizumab Failure-Were Potentially Dangerous Signs Missed in Clinical Trials?

Avasarala J.

Drug Target Insights. 2018 Jun 29;12:1177392818785136. doi: 10.1177/1177392818785136. eCollection 2018.

5.

Reader response: Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.

Avasarala J.

Neurology. 2018 Jul 3;91(1):51. doi: 10.1212/WNL.0000000000005727. No abstract available.

PMID:
29967207
6.

Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis.

Avasarala JR, Jones JR, Rogers CR.

Mult Scler Relat Disord. 2018 May;22:157-160. doi: 10.1016/j.msard.2018.04.004. Epub 2018 Apr 21.

PMID:
29751260
7.

Anti-CD20 Cell Therapies in Multiple Sclerosis-A Fixed Dosing Schedule for Ocrelizumab is Overkill.

Avasarala J.

Drug Target Insights. 2017 Oct 25;11:1177392817737515. doi: 10.1177/1177392817737515. eCollection 2017.

8.

It's Time For Combination Therapies: in Multiple Sclerosis.

Avasarala J.

Innov Clin Neurosci. 2017 Jun 1;14(5-6):28-30. eCollection 2017 May-Jun.

9.

Redefining Acute Relapses in Multiple Sclerosis: Implications for Phase 3 Clinical Trials and Treatment Algorithms.

Avasarala J.

Innov Clin Neurosci. 2017 Apr 1;14(3-4):38-40. eCollection 2017 Mar-Apr.

10.

Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?

Avasarala J, Jain S, Urrea-Mendoza E.

J Clin Pharmacol. 2017 Nov;57(11):1415-1418. doi: 10.1002/jcph.945. Epub 2017 May 25. No abstract available.

PMID:
28543950
11.

Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.

Avasarala J.

Neurology. 2017 May 9;88(19):1875. doi: 10.1212/WNL.0000000000003929. No abstract available.

PMID:
28483993
12.

Leptomeningeal Enhancement for Multiple Sclerosis: Another Radiological Biomarker for a Relapse?

Avasarala J.

JAMA Neurol. 2017 Jun 1;74(6):745-746. doi: 10.1001/jamaneurol.2017.0123. No abstract available.

PMID:
28384731
13.

Optimization of acute stroke care in the emergency department: a call for better utilization of healthcare resources amid growing shortage of neurologists in the United States.

Avasarala J, Wesley K.

CNS Spectr. 2018 Aug;23(4):248-250. doi: 10.1017/S109285291700013X. Epub 2017 Feb 17. No abstract available.

PMID:
28209212
14.

Standardization of MRI data and disability quantification in the post-EPIC era.

Avasarala J.

CNS Spectr. 2018 Feb;23(1):8-9. doi: 10.1017/S1092852917000153. Epub 2017 Feb 9. No abstract available.

PMID:
28179041
15.

Stroke Diagnosis and Treatment in the Emergency Department-Reply.

Avasarala J.

JAMA Neurol. 2017 Mar 1;74(3):362-363. doi: 10.1001/jamaneurol.2016.5564. No abstract available.

PMID:
28114619
16.

Is a Neurologist Needed to Diagnose Acute Stroke in the Emergency Department?: Too Many Cooks Might Spoil the Broth.

Avasarala J.

JAMA Neurol. 2016 Nov 1;73(11):1273-1274. doi: 10.1001/jamaneurol.2016.2527. No abstract available.

PMID:
27599026
17.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.

Avasarala J, Sotirchos ES, Bhargava P, Calabresi PA.

Neurology. 2016 Jul 26;87(4):445-6. doi: 10.1212/WNL.0000000000002937. No abstract available.

PMID:
27462039
18.

Overdiagnosis of idiopathic intracranial hypertension.

Avasarala J, Biousse V, Newman NJ.

Neurology. 2016 Jun 7;86(23):2216. doi: 10.1212/WNL.0000000000002756. No abstract available.

PMID:
27272036
19.

Applying the Principles of McDonaldization to Medicine.

Avasarala JR.

JAMA Neurol. 2016 Apr;73(4):478-9. doi: 10.1001/jamaneurol.2015.4719. No abstract available.

PMID:
26881421
20.

Diagnosing Lymphomatosis Cerebri.

Avasarala J.

JAMA Neurol. 2015 Dec;72(12):1536. doi: 10.1001/jamaneurol.2015.2672. No abstract available.

PMID:
26658974
21.

Computer-aided Therapeutics in Treating Autoimmune Encephalitis.

Avasarala J.

JAMA Neurol. 2016 Jan;73(1):127-8. doi: 10.1001/jamaneurol.2015.3516. No abstract available.

PMID:
26619361
23.

Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?

Avasarala J, Zachariah P.

J Neurol Sci. 2015 Nov 15;358(1-2):417-8. doi: 10.1016/j.jns.2015.08.018. Epub 2015 Aug 12.

PMID:
26303623
24.

Multiple sclerosis in US minority populations: Clinical practice insights.

Avasarala J.

Neurol Clin Pract. 2015 Jun;5(3):186-187. doi: 10.1212/01.CPJ.0000466889.88876.d0. No abstract available.

25.

Clinically isolated syndrome--Rethinking the diagnosis.

Avasarala JR.

J Neurol Sci. 2015;353(1-2):79-80. doi: 10.1016/j.jns.2015.04.008. Epub 2015 Apr 14.

PMID:
25940324
26.

Newer multiple sclerosis drugs and disability scores-are key data analyses missing?

Avasarala JR.

J Clin Pharmacol. 2015 Nov;55(11):1218-20. doi: 10.1002/jcph.535. Epub 2015 Jun 14. No abstract available.

PMID:
25939590
27.

The TOUCH program and natalizumab: Fundamental flaw in patient protection.

Avasarala J.

Version 3. F1000Res. 2015 Dec 15 [revised 2016 Jan 1];4:1450. doi: 10.12688/f1000research.7513.3. eCollection 2015.

28.

Inadequacy of clinical trial designs and data to control for the confounding impact of race/ethnicity in response to treatment in multiple sclerosis.

Avasarala J.

JAMA Neurol. 2014 Aug;71(8):943-4. doi: 10.1001/jamaneurol.2014.79. No abstract available.

PMID:
24911916
29.

Cerebrospinal fluid proteomics - work in progress.

Avasarala JR.

Eur J Neurol. 2008 Sep;15(9):891-2. doi: 10.1111/j.1468-1331.2008.02238.x. No abstract available.

PMID:
18796074
30.

Microarray analysis in B cells among siblings with/without MS - role for transcription factor TCF2.

Avasarala JR, Chittur SV, George AD, Tine JA.

BMC Med Genomics. 2008 Jan 31;1:2. doi: 10.1186/1755-8794-1-2.

31.

Analysis of NAMCS data for multiple sclerosis, 1998-2004.

Avasarala JR, O'Donovan CA, Roach SE, Camacho F, Feldman SR.

BMC Med. 2007 Apr 5;5:6.

32.

Ventricular obstruction from neurocysticercosis.

Gordon E, Cartwright M, Avasarala J.

Arch Neurol. 2005 Jun;62(6):1018. No abstract available.

PMID:
15956179
35.

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS.

Avasarala JR.

Neurology. 2004 Aug 10;63(3):599; author reply 599. No abstract available.

PMID:
15304618
36.
37.

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.

Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE.

Mult Scler. 2003 Feb;9(1):59-62.

PMID:
12617270
39.

Oligoclonal band number as a marker for prognosis in multiple sclerosis.

Avasarala JR, Cross AH, Trotter JL.

Arch Neurol. 2001 Dec;58(12):2044-5.

PMID:
11735778
40.

Blood pressure reduction and stroke.

Pesola GR, Avasarala J, Pesola DA.

J Emerg Med. 2001 Oct;21(3):290-1. No abstract available.

PMID:
11604289
41.

Surrogate markers in multiple sclerosis.

Avasarala JR.

Arch Neurol. 2001 May;58(5):834. No abstract available.

PMID:
11346385
42.

Inflammatory trigeminal sensory neuropathy.

Avasarala J.

Neurology. 1997 Jul;49(1):308. No abstract available.

PMID:
9222216
43.

Distribution of peptidases in cultured cells from middle ear mucosa: prolyl endopeptidase is localized in fibroblasts and dipeptidyl peptidase IV and II in epithelial cells.

Avasarala JR, Naoi M, Sasaki S, Ueda M, Saga S, Suzuki T, Yanagita N, Nagatsu T.

Biochem Med Metab Biol. 1991 Jun;45(3):355-8.

PMID:
1675574

Supplemental Content

Loading ...
Support Center